Opinion|Videos|October 4, 2024
Best Treatment Selection in Clear-Cell RCC
Medical experts describe the decision-making process between choosing an IO-IO vs an IO-TKI regimen for first-line treatment, considering factors such as safety profile and response in both community and academic settings.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Describe your thought process when deciding between an IO-IO regimen and IO-TKI regimen for 1L.(56:23- END)
What factors might you consider (safety profile, best response, etc) in community vs academic settings?
Advertisement
Related to this article
Matthew Matasar, MD, reflected on how quickly oncology has moved from skepticism to nimble adoption of AI, and what he expects from the field going forward.
Advertisement
Advertisement
Trending on CancerNetwork
1
IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma
2
WCLC 2026: How Will The Small Cell Lung Cancer Paradigm Change?
3
SOHO 2026: Key Updates Across the Multiple Myeloma Continuum
4
Secondary T-Cell Malignancies: Identifying and Counseling After CAR T-Cell Therapy
5